{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:41:19Z","timestamp":1791726079321,"version":"4.3.4"},"reference-count":419,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:p>The Sugen 5416\/hypoxia (Su\/Hx) rat model of pulmonary arterial hypertension (PAH) demonstrates most of the distinguishing features of PAH in humans, including increased wall thickness and obstruction of the small pulmonary arteries along with plexiform lesion formation. Recently, significant advancement has been made describing the epidemiology, genomics, biochemistry, physiology, and pharmacology in Su\/Hx challenge in rats. For example, there are differences in the overall reactivity to Su\/Hx challenge in different rat strains and only female rats respond to estrogen treatments. These conditions are also encountered in human subjects with PAH. Also, there is a good translation in both the biochemical and metabolic pathways in the pulmonary vasculature and right heart between Su\/Hx rats and humans, particularly during the transition from the adaptive to the nonadaptive phase of right heart failure. Noninvasive techniques such as echocardiography and magnetic resonance imaging have recently been used to evaluate the progression of the pulmonary vascular and cardiac hemodynamics, which are important parameters to monitor the efficacy of drug treatment over time. From a pharmacological perspective, most of the compounds approved clinically for the treatment of PAH are efficacious in Su\/Hx rats. Several compounds that show efficacy in Su\/Hx rats have advanced into phase II\/phase III studies in humans with positive results. Results from these drug trials, if successful, will provide additional treatment options for patients with PAH and will also further validate the excellent translation that currently exists between Su\/Hx rats and the human PAH condition.<\/jats:p>","DOI":"10.1089\/jamp.2024.0016","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:51:01Z","timestamp":1728579061000},"page":"241-283","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Overview of the Biology and Pharmacology in Sugen\/Hypoxia-Induced Pulmonary Hypertension in Rats"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-8134","authenticated-orcid":false,"given":"Michel R.","family":"Corboz","sequence":"first","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Stautberg","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cipolla","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00038410"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00048"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-45805-1_5"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00217.2009"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.08.003"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.02.005"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2014-0488OC"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/678508"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2016.04.001"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2018"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020977300"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019845611"},{"issue":"3","key":"e_1_3_6_17_2","first-page":"201","article-title":"Modern invasive hemodynamic assessment of pulmonary hypertension","volume":"95","author":"Pagnamenta A","year":"2018","unstructured":"Pagnamenta A, , Lador F, , Azzola A, et al. Modern invasive hemodynamic assessment of pulmonary hypertension. Respiratory, 2018; 95(3):201\u2013211; doi: 10.1159\/000484942","journal-title":"Respiratory"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00741-2015"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00057.2020"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2018-0329TR"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1160ST"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.84"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019832226"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319971"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0343com"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927681"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211051188"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1200LE"},{"issue":"3","key":"e_1_3_6_31_2","first-page":"253","article-title":"The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension","volume":"81","author":"Sakao S","year":"2011","unstructured":"Sakao S, , Tatsumi K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiratory, 2011; 81(3):253\u2013261; doi: 10.1159\/000322011","journal-title":"Respiratory"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244798"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00057.2016"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00728.2013"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/688931"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00204813"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00381.2018"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.052"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000508"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00169.2007"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174484"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001174"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2079OC"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000352"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043433"},{"issue":"1","key":"e_1_3_6_47_2","first-page":"42","article-title":"Strain differences in pulmonary function of laboratory rats","volume":"32","author":"Boyd RL","year":"1982","unstructured":"Boyd RL, , Halderman LW, , Harris JO, et al. Strain differences in pulmonary function of laboratory rats. Lab Anim Sci, 1982; 32(1):42\u201343.","journal-title":"Lab Anim Sci"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00100.2020"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.37117.x"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.2000.278.5.L981"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.4236\/ojmip.2012.23012"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1991.70.4.1861"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/10739680903114268"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.08.016"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy258"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000195509"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.4_Pt_1.793"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65592"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19300"},{"issue":"1","key":"e_1_3_6_60_2","first-page":"H62","article-title":"Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery","volume":"240","author":"Rabinovitch M","year":"1981","unstructured":"Rabinovitch M, , Gamble WJ, , Miettinen OS, et al. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol, 1981; 240(1):H62\u2013H72; doi: 10.1152\/ajpheart.1981.240.1.H62","journal-title":"Am J Physiol"},{"key":"e_1_3_6_61_2","article-title":"Sex and age differences in pulmonary vascular responses in a chronic hypoxia rat model","volume":"54","author":"Olea E","year":"2019","unstructured":"Olea E, , Prieto-Lloret J, , Gordillo A, et al. Sex and age differences in pulmonary vascular responses in a chronic hypoxia rat model. Eur Res J, 2019; 54; doi: 10.1183\/13993003.congress-2019","journal-title":"Eur Res J"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-3114"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.10.137"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1291"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2017-0260OC"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202006-671OC"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0483OC"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00006.2015"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217702055"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2510-4"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00544-5"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.002881"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092585"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2018.04.093"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2018.05.026"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019897513"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201509-599FR"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15016"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.09.054"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1246"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00951"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.10.005"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.105040"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020910976"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1086\/687767"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00979.2001"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00114.2010"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019841987"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy004"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303848"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3261fje"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b01003"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000261658.12024.18"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2012.tb00402.x"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201812-2275OC"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006674"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018790905"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao0303"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00746.2012"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217741429"},{"key":"e_1_3_6_101_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.966127"},{"key":"e_1_3_6_102_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03261"},{"key":"e_1_3_6_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-016-0663-4"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00169.2015"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012086"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.01.012"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112338"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120157"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S236743"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118655"},{"key":"e_1_3_6_111_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.006980"},{"key":"e_1_3_6_112_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00259.2017"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14472"},{"key":"e_1_3_6_114_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105426"},{"key":"e_1_3_6_115_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.2262571"},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00188013"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240692"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa200"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.09.013"},{"key":"e_1_3_6_120_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020947283"},{"key":"e_1_3_6_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000141"},{"key":"e_1_3_6_122_2","first-page":"1489","article-title":"Improvements in the dysfunctional right ventricle with Macitentan treatment in a sugen\/hypoxic rat model of pulmonary hypertension","author":"Murphy G","year":"2020","unstructured":"Murphy G, , Jayasekera G, , Mullin J, et al. Improvements in the dysfunctional right ventricle with Macitentan treatment in a sugen\/hypoxic rat model of pulmonary hypertension. Eur Resp J, 2020; 1489; doi: 10.1183\/13993003","journal-title":"Eur Resp J"},{"issue":"12","key":"e_1_3_6_123_2","first-page":"1357","article-title":"Pulmonary haemodynamics are correlated with intimal lesions in a rat model of severe PAH: Attenuation of pulmonary vascular remodelling with ambrisentan","volume":"31","author":"Takeuchi T","year":"2016","unstructured":"Takeuchi T, , Sakao S, , Kato F, et al. Pulmonary haemodynamics are correlated with intimal lesions in a rat model of severe PAH: Attenuation of pulmonary vascular remodelling with ambrisentan. Histol Histopathol, 2016; 31(12):1357\u20131365; doi: 10.14670\/HH-11-764","journal-title":"Histol Histopathol"},{"key":"e_1_3_6_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.02.003"},{"key":"e_1_3_6_125_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02449-2016"},{"key":"e_1_3_6_126_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-2061LE"},{"key":"e_1_3_6_127_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2435"},{"key":"e_1_3_6_128_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00527.2016"},{"key":"e_1_3_6_129_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"e_1_3_6_130_2","first-page":"A1187","article-title":"The SPECTRA study: A phase 2a single-arm, open-label, multicenter exploratory study to assess the effects of sotatercept for the treatment of Pulmonary Arterial Hypertension (PAH)","author":"Waxman AB","year":"2021","unstructured":"Waxman AB, , Risbano MG, , Frantz RP, et al. The SPECTRA study: A phase 2a single-arm, open-label, multicenter exploratory study to assess the effects of sotatercept for the treatment of Pulmonary Arterial Hypertension (PAH). Am J Resp Crit Care Med, 2021; A1187\u2013A1187; doi: 10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1187","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_6_131_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11435-x"},{"key":"e_1_3_6_132_2","unstructured":"ClinicalTrials Gov. A study of sotatercept for the treatment of pulmonary arterial hypertension (STELLAR). 2021;7. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04576988"},{"issue":"1","key":"e_1_3_6_133_2","article-title":"Sotatercept phase 3 program design and rationale: A novel treatment for pulmonary arterial hypertension","volume":"144","author":"Preston IR","year":"2021","unstructured":"Preston IR, , Badesch D, , Ghofrani HA, et al. Sotatercept phase 3 program design and rationale: A novel treatment for pulmonary arterial hypertension. Circulation, 2021; 144(Suppl 1); doi: 10.1161\/circ.144.suppl_1.10188","journal-title":"Circulation"},{"key":"e_1_3_6_134_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0443"},{"key":"e_1_3_6_135_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.70.174"},{"key":"e_1_3_6_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.08.002"},{"key":"e_1_3_6_137_2","first-page":"3148259","article-title":"Effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction: A prospective intervention study","volume":"2018","author":"Zhang X","year":"2018","unstructured":"Zhang X, , Zhang X, , Wang S, et al. Effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction: A prospective intervention study. Can Respir J, 2018; 2018:3148259; doi: 10.1155\/2018\/3148259","journal-title":"Can Respir J"},{"key":"e_1_3_6_138_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-008-9315-z"},{"key":"e_1_3_6_139_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-1015"},{"key":"e_1_3_6_140_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00095211"},{"key":"e_1_3_6_141_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.029470"},{"key":"e_1_3_6_142_2","doi-asserted-by":"publisher","DOI":"10.1111\/chd.12764"},{"key":"e_1_3_6_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.101"},{"key":"e_1_3_6_144_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b01061"},{"key":"e_1_3_6_145_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00208"},{"key":"e_1_3_6_146_2","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211057071"},{"key":"e_1_3_6_147_2","article-title":"Seralutinib for the treatment of Pulmonary Arterial Hypertension (PAH): Results from the phase 2 TORREY trial","volume":"207","author":"Frantz RP","year":"2023","unstructured":"Frantz RP, , McLaughlin VV, , Sahay S, et al. Seralutinib for the treatment of Pulmonary Arterial Hypertension (PAH): Results from the phase 2 TORREY trial. Am J Resp Crit Care Med, 2023; 207.","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_6_148_2","first-page":"OA742","article-title":"Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY phase 2 imaging substudy","author":"Zamanian R","year":"2023","unstructured":"Zamanian R, , Rahaghi FN, , Howard L, et al. Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY phase 2 imaging substudy. Eur Respir J, 2023; OA742\u2013S67.","journal-title":"Eur Respir J"},{"key":"e_1_3_6_149_2","first-page":"140","article-title":"Gb002, a novel inhaled Pdgfr kinase inhibitor, demonstrates efficacy in the Su5416 hypoxia rat model of pulmonary arterial hypertension (PAH)","author":"Galkin A","year":"2019","unstructured":"Galkin A, , Clemons B, , Garcia E, et al. Gb002, a novel inhaled Pdgfr kinase inhibitor, demonstrates efficacy in the Su5416 hypoxia rat model of pulmonary arterial hypertension (PAH). Circulation, 2019; 140.","journal-title":"Circulation"},{"key":"e_1_3_6_150_2","first-page":"3550","article-title":"Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)","volume":"56","author":"Galkin A","year":"2020","unstructured":"Galkin A, , Sitapara R, , Clemons B, et al. Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH). Eur J Resp, 2020; 56:3550; doi: 10.1183\/13993003.congress-2020.3550","journal-title":"Eur J Resp"},{"key":"e_1_3_6_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.05.025"},{"key":"e_1_3_6_152_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0371OC"},{"key":"e_1_3_6_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.217"},{"key":"e_1_3_6_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.03.009"},{"key":"e_1_3_6_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00032-1"},{"key":"e_1_3_6_156_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201703-0502OC"},{"key":"e_1_3_6_157_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020922810"},{"key":"e_1_3_6_158_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201412-2291OC"},{"key":"e_1_3_6_159_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009111-699OC"},{"key":"e_1_3_6_160_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.015693"},{"key":"e_1_3_6_161_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201801-0195LE"},{"key":"e_1_3_6_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30356-8"},{"key":"e_1_3_6_163_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201801659R"},{"key":"e_1_3_6_164_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-2025LE"},{"key":"e_1_3_6_165_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95240"},{"key":"e_1_3_6_166_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001429"},{"key":"e_1_3_6_167_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00215514"},{"key":"e_1_3_6_168_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-020-02494-6"},{"key":"e_1_3_6_169_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0335OC"},{"key":"e_1_3_6_170_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019898030"},{"key":"e_1_3_6_171_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.094722"},{"key":"e_1_3_6_172_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-91"},{"key":"e_1_3_6_173_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00238.2021"},{"issue":"5","key":"e_1_3_6_174_2","first-page":"187","article-title":"Reduction in pulmonary artery pressures with use of sacubitril\/valsartan","volume":"20","author":"De Simone V","year":"2019","unstructured":"De Simone V, , Guarise P, , Zanotto G, et al. Reduction in pulmonary artery pressures with use of sacubitril\/valsartan. J Cardiol Cases, 2019; 20(5):187\u2013190; doi: 10.1016\/j.jccase.2019.08.006","journal-title":"J Cardiol Cases"},{"key":"e_1_3_6_175_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006696"},{"key":"e_1_3_6_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.06.065"},{"key":"e_1_3_6_177_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819"},{"key":"e_1_3_6_178_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I2A43"},{"key":"e_1_3_6_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.075"},{"key":"e_1_3_6_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2018.09.021"},{"key":"e_1_3_6_181_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311992"},{"key":"e_1_3_6_182_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202109-2182LE"},{"key":"e_1_3_6_183_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.01.013"},{"key":"e_1_3_6_184_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129433"},{"key":"e_1_3_6_185_2","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.2023.38.S1.5725371"},{"key":"e_1_3_6_186_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07353"},{"key":"e_1_3_6_187_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018349"},{"key":"e_1_3_6_188_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1024OC"},{"key":"e_1_3_6_189_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-10-6"},{"key":"e_1_3_6_190_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.237933"},{"key":"e_1_3_6_191_2","first-page":"205","article-title":"Rodatristat ethyl monotherapy and combination with Ambrisentan reverses incidence of vascular occlusions to baseline normoxic levels in the rat SUGEN-hypoxia model of pulmonary arterial hypertension","author":"Palacios M","year":"2022","unstructured":"Palacios M, , Wring S. Rodatristat ethyl monotherapy and combination with Ambrisentan reverses incidence of vascular occlusions to baseline normoxic levels in the rat SUGEN-hypoxia model of pulmonary arterial hypertension. Am J Resp Crit Care Med, 2022; 205.","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_6_192_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02463-2020"},{"key":"e_1_3_6_193_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96462"},{"key":"e_1_3_6_194_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.681473"},{"key":"e_1_3_6_195_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00362.2020"},{"key":"e_1_3_6_196_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2018-0232OC"},{"key":"e_1_3_6_197_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15000"},{"key":"e_1_3_6_198_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3770-0"},{"key":"e_1_3_6_199_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008325150"},{"issue":"9","key":"e_1_3_6_200_2","first-page":"83","article-title":"Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension","volume":"84","author":"Martyniuk TV","year":"2012","unstructured":"Martyniuk TV, , Arkhipova OA, , Kobal EA, et al. Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension. Ter Arkh, 2012; 84(9):83\u201388.","journal-title":"Ter Arkh"},{"key":"e_1_3_6_201_2","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12699"},{"key":"e_1_3_6_202_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507273330403"},{"key":"e_1_3_6_203_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282402"},{"key":"e_1_3_6_204_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"e_1_3_6_205_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011408200"},{"key":"e_1_3_6_206_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-1703-1"},{"key":"e_1_3_6_207_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.03.012"},{"key":"e_1_3_6_208_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703090"},{"key":"e_1_3_6_209_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0289OC"},{"key":"e_1_3_6_210_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.266023"},{"key":"e_1_3_6_211_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753465809369619"},{"key":"e_1_3_6_212_2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2016"},{"key":"e_1_3_6_213_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-4"},{"key":"e_1_3_6_214_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2010.04.006"},{"key":"e_1_3_6_215_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669227"},{"key":"e_1_3_6_216_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.527077"},{"key":"e_1_3_6_217_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.04.026"},{"key":"e_1_3_6_218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.06.135"},{"key":"e_1_3_6_219_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242099"},{"key":"e_1_3_6_220_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020548"},{"key":"e_1_3_6_221_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.02.002"},{"issue":"11","key":"e_1_3_6_222_2","first-page":"5144","article-title":"Safety, tolerability, and pharmacokinetics of treprostinil palmitil inhalation powder for pulmonary hypertension: A phase 1, randomized, double-blind, single- and multiple-dose study","volume":"39","author":"Ismat FA","year":"2022","unstructured":"Ismat FA, , Usansky HH, , Villa R, et al. Safety, tolerability, and pharmacokinetics of treprostinil palmitil inhalation powder for pulmonary hypertension: A phase 1, randomized, double-blind, single- and multiple-dose study. Adv Ther, 2022; 39(11):5144\u20135157; doi: 10.1007\/s12325-022-02296-x","journal-title":"Adv Ther"},{"key":"e_1_3_6_223_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.117.123"},{"key":"e_1_3_6_224_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"e_1_3_6_225_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"e_1_3_6_226_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-005-0925-4"},{"key":"e_1_3_6_227_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01518"},{"key":"e_1_3_6_228_2","doi-asserted-by":"publisher","DOI":"10.1159\/000500424"},{"key":"e_1_3_6_229_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701367"},{"key":"e_1_3_6_230_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00698"},{"key":"e_1_3_6_231_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-1185-1_5"},{"key":"e_1_3_6_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.10.029"},{"key":"e_1_3_6_233_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239665"},{"key":"e_1_3_6_234_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"issue":"2","key":"e_1_3_6_235_2","first-page":"14","article-title":"Nitric oxide and pulmonary arterial hypertension","volume":"2017","author":"Chester AH","year":"2017","unstructured":"Chester AH, , Yacoub MH, , Moncada S. Nitric oxide and pulmonary arterial hypertension. Glob Cardiol Sci Pract, 2017; 2017(2):14; doi: 10.21542\/gcsp.2017.14","journal-title":"Glob Cardiol Sci Pract"},{"key":"e_1_3_6_236_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_3_6_237_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"issue":"3","key":"e_1_3_6_238_2","first-page":"257","article-title":"The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases","volume":"2014","author":"Butrous G","year":"2014","unstructured":"Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract, 2014; 2014(3):257\u2013290; doi: 10.5339\/gcsp.2014.42","journal-title":"Glob Cardiol Sci Pract"},{"key":"e_1_3_6_239_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655266"},{"key":"e_1_3_6_240_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2003.12.023"},{"key":"e_1_3_6_241_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43225-3"},{"key":"e_1_3_6_242_2","article-title":"Female rats respond better to Sildenafil treatment in SuHx-induced PAH model","author":"Gagnon S","year":"2020","unstructured":"Gagnon S, , Brodeur C, , Laurent CE, et al. Female rats respond better to Sildenafil treatment in SuHx-induced PAH model. Internal Report, 2020.","journal-title":"Internal Report"},{"key":"e_1_3_6_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173658"},{"key":"e_1_3_6_244_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.04.049"},{"key":"e_1_3_6_245_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"e_1_3_6_246_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-45805-1_12"},{"issue":"11","key":"e_1_3_6_247_2","first-page":"749","article-title":"Riociguat (Adempas): A novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"39","author":"Khaybullina D","year":"2014","unstructured":"Khaybullina D, , Patel A, , Zerilli T. Riociguat (Adempas): A novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T, 2014; 39(11):749\u2013758.","journal-title":"P T"},{"key":"e_1_3_6_248_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.10"},{"issue":"1","key":"e_1_3_6_249_2","article-title":"Correction: Improvement of right heart structure and function by BAY41-8543 in pulmonary artery banded mice","volume":"11","author":"Janssen W","year":"2011","unstructured":"Janssen W, , Schymura Y, , Wietelmann A, et al. Correction: Improvement of right heart structure and function by BAY41-8543 in pulmonary artery banded mice. BMC Pharmacol, 2011; 11(S1); doi: 10.1186\/1471-2210-11-S1-P80","journal-title":"BMC Pharmacol"},{"key":"e_1_3_6_250_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.06.005"},{"key":"e_1_3_6_251_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30532-4"},{"key":"e_1_3_6_252_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc7734"},{"key":"e_1_3_6_253_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.6.2247"},{"key":"e_1_3_6_254_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.3.2104059"},{"key":"e_1_3_6_255_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00054804"},{"key":"e_1_3_6_256_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S133921"},{"key":"e_1_3_6_257_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.11.026"},{"key":"e_1_3_6_258_2","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12124"},{"key":"e_1_3_6_259_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00129.2014"},{"key":"e_1_3_6_260_2","first-page":"PA5056","article-title":"Macitentan treatment improves the dysfunctional right ventricle in a sugen\/hypoxic rat model of pulmonary hypertension","author":"Murphy G","year":"2019","unstructured":"Murphy G, , Jayasekera G, , Mullin J, et al. Macitentan treatment improves the dysfunctional right ventricle in a sugen\/hypoxic rat model of pulmonary hypertension. Eur Respir J, 2019; PA5056; doi: 10.1183\/13993003","journal-title":"Eur Respir J"},{"key":"e_1_3_6_261_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"e_1_3_6_262_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12856"},{"key":"e_1_3_6_263_2","first-page":"1675","article-title":"Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension","volume":"10","author":"Monaco TJ","year":"2016","unstructured":"Monaco TJ, , Davila CD. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther, 2016; 10:1675\u20131682; doi: 10.2147\/DDDT.S88612","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_6_264_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13033"},{"key":"e_1_3_6_265_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2021.07.027"},{"key":"e_1_3_6_266_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S4711"},{"key":"e_1_3_6_267_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.24.8467-8477.2002"},{"key":"e_1_3_6_268_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S297500"},{"key":"e_1_3_6_269_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(24)01321-8"},{"key":"e_1_3_6_270_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-957933"},{"key":"e_1_3_6_271_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.10.240"},{"key":"e_1_3_6_272_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.02.002"},{"key":"e_1_3_6_273_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.301141"},{"key":"e_1_3_6_274_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002561"},{"key":"e_1_3_6_275_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002740"},{"key":"e_1_3_6_276_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018759125"},{"key":"e_1_3_6_277_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148657"},{"key":"e_1_3_6_278_2","article-title":"Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs placebo in subjects with pulmonary arterial hypertension: Results of a double blind, randomized, prospective Phase IIa study","volume":"2012","author":"Ghofrani HA","year":"2012","unstructured":"Ghofrani HA, , Vonk-Noordegraaf A, , Behr J, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs placebo in subjects with pulmonary arterial hypertension: Results of a double blind, randomized, prospective Phase IIa study. Am J Respir Crit Care Med, 2012; 2012; doi: 10.1164\/AJRCCMCONFERENCE.2012.185.1_MEETINGABSTRACTS.A2496","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_6_279_2","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12088"},{"key":"e_1_3_6_280_2","first-page":"195","article-title":"Kar5585, a first-in-class oral tryptophan Hydroxylase 1 (tph1) inhibitor as a novel candidate for the treatment of pulmonary arterial hypertension","author":"Paralkar V","year":"2017","unstructured":"Paralkar V, , Pearson P, , Mason JW, et al. Kar5585, a first-in-class oral tryptophan Hydroxylase 1 (tph1) inhibitor as a novel candidate for the treatment of pulmonary arterial hypertension. Am J Resp Crit Care Med, 2017; 195.","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_6_281_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00217"},{"key":"e_1_3_6_282_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307634"},{"key":"e_1_3_6_283_2","doi-asserted-by":"publisher","DOI":"10.1016\/B0-12-370879-6\/00330-6"},{"key":"e_1_3_6_284_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0095RT"},{"key":"e_1_3_6_285_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.05.051"},{"key":"e_1_3_6_286_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00238.2014"},{"key":"e_1_3_6_287_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0335OC"},{"key":"e_1_3_6_288_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14079"},{"key":"e_1_3_6_289_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.5.7735624"},{"key":"e_1_3_6_290_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.182014"},{"key":"e_1_3_6_291_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.933762"},{"key":"e_1_3_6_292_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.6_suppl.572S-a"},{"key":"e_1_3_6_293_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/720305"},{"key":"e_1_3_6_294_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217735820"},{"key":"e_1_3_6_295_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.2001.280.1.L39"},{"key":"e_1_3_6_296_2","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.187"},{"key":"e_1_3_6_297_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12304"},{"key":"e_1_3_6_298_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06370"},{"key":"e_1_3_6_299_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019882635"},{"key":"e_1_3_6_300_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.1.9704003"},{"key":"e_1_3_6_301_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00476.2019"},{"key":"e_1_3_6_302_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019865704"},{"key":"e_1_3_6_303_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"e_1_3_6_304_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"e_1_3_6_305_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.177"},{"key":"e_1_3_6_306_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003521"},{"key":"e_1_3_6_307_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1356494"},{"key":"e_1_3_6_308_2","doi-asserted-by":"publisher","DOI":"10.1086\/674881"},{"key":"e_1_3_6_309_2","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1772106"},{"key":"e_1_3_6_310_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.34.1785"},{"issue":"5","key":"e_1_3_6_311_2","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen MH","year":"2002","unstructured":"Cohen MH, , Williams G, , Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 2002; 8(5):935\u2013942.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"e_1_3_6_312_2","first-page":"3034","article-title":"Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher R","year":"2002","unstructured":"Dagher R, , Cohen M, , Williams G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res, 2002; 8(10):3034\u20133038.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_313_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc051946"},{"key":"e_1_3_6_314_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-2-200607180-00020"},{"key":"e_1_3_6_315_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.064097"},{"key":"e_1_3_6_316_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001460"},{"key":"e_1_3_6_317_2","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211052823"},{"key":"e_1_3_6_318_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920927602"},{"key":"e_1_3_6_319_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-500-2_27"},{"key":"e_1_3_6_320_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.026"},{"key":"e_1_3_6_321_2","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v2.i10.316"},{"key":"e_1_3_6_322_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12010008"},{"key":"e_1_3_6_323_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00078-2019"},{"key":"e_1_3_6_324_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2020-0528OC"},{"key":"e_1_3_6_325_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.01.1238"},{"key":"e_1_3_6_326_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"e_1_3_6_327_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213558"},{"key":"e_1_3_6_328_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.08.009"},{"key":"e_1_3_6_329_2","first-page":"A4409","article-title":"ABI-009, nabisirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension","author":"Simon M","year":"2020","unstructured":"Simon M, , Gomberg-Maitland M, , Oudiz RJ, et al. ABI-009, nabisirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension. Am J Resp Crit Care Med, 2020; A4409\u2013A4409; doi: 10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A4409","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_6_330_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201911-2137OC"},{"key":"e_1_3_6_331_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.24645"},{"key":"e_1_3_6_332_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.01.001"},{"key":"e_1_3_6_333_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.758763"},{"key":"e_1_3_6_334_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201510-1955OC"},{"key":"e_1_3_6_335_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137558"},{"key":"e_1_3_6_336_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202001-0078OC"},{"key":"e_1_3_6_337_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1130ED"},{"key":"e_1_3_6_338_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.883843"},{"key":"e_1_3_6_339_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315229"},{"key":"e_1_3_6_340_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021494"},{"key":"e_1_3_6_341_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032391"},{"key":"e_1_3_6_342_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02061-2019"},{"key":"e_1_3_6_343_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018812053"},{"key":"e_1_3_6_344_2","doi-asserted-by":"publisher","DOI":"10.1086\/674755"},{"key":"e_1_3_6_345_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41854-2"},{"issue":"4","key":"e_1_3_6_346_2","first-page":"326","article-title":"Rosiglitazone: An agent from the thiazolidinedione class for the treatment of type 2 diabetes","volume":"2","author":"Cheng-Lai A","year":"2000","unstructured":"Cheng-Lai A, , Levine A. Rosiglitazone: An agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis, 2000; 2(4):326\u2013333.","journal-title":"Heart Dis"},{"key":"e_1_3_6_347_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00491.2005"},{"key":"e_1_3_6_348_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2016.08.005"},{"key":"e_1_3_6_349_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149011"},{"key":"e_1_3_6_350_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy186"},{"key":"e_1_3_6_351_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214697"},{"key":"e_1_3_6_352_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01804-1"},{"key":"e_1_3_6_353_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.047"},{"key":"e_1_3_6_354_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-547OC"},{"key":"e_1_3_6_355_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.027451"},{"key":"e_1_3_6_356_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0679-6"},{"key":"e_1_3_6_357_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000140724.90898.D3"},{"key":"e_1_3_6_358_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003703"},{"key":"e_1_3_6_359_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0411OC"},{"key":"e_1_3_6_360_2","doi-asserted-by":"publisher","DOI":"10.1086\/675984"},{"key":"e_1_3_6_361_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011343"},{"key":"e_1_3_6_362_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19207"},{"key":"e_1_3_6_363_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20150469"},{"key":"e_1_3_6_364_2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:1:1"},{"key":"e_1_3_6_365_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.07.007"},{"key":"e_1_3_6_366_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42234-019-0036-9"},{"key":"e_1_3_6_367_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42234-022-00091-1"},{"key":"e_1_3_6_368_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08750-9"},{"key":"e_1_3_6_369_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.123.323679"},{"key":"e_1_3_6_370_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.77.4.525"},{"key":"e_1_3_6_371_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002569"},{"key":"e_1_3_6_372_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2014.11.025"},{"key":"e_1_3_6_373_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15154"},{"key":"e_1_3_6_374_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2016.09.007"},{"key":"e_1_3_6_375_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"e_1_3_6_376_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670"},{"key":"e_1_3_6_377_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.114-a160"},{"key":"e_1_3_6_378_2","doi-asserted-by":"publisher","DOI":"10.1530\/VB-19-0030"},{"key":"e_1_3_6_379_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14932"},{"key":"e_1_3_6_380_2","doi-asserted-by":"publisher","DOI":"10.1086\/675986"},{"key":"e_1_3_6_381_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201007-1106OC"},{"key":"e_1_3_6_382_2","first-page":"259","article-title":"Inhibition of histone deacetylase activity reduces pulmonary vascular remodeling and inflammation in experimental pulmonary hypertension","volume":"8","author":"Kurakula KB","year":"2022","unstructured":"Kurakula KB, , Sun DE, , Bogaard HJ, et al. Inhibition of histone deacetylase activity reduces pulmonary vascular remodeling and inflammation in experimental pulmonary hypertension. Eur Resp J, 2022; 8:259; doi: 10.1183\/23120541.LSC-2022.259","journal-title":"Eur Resp J"},{"issue":"2","key":"e_1_3_6_383_2","article-title":"Selective inhibition of histone deacetylases reverses vascular remodelling and improves right ventricle function in pulmonary hypertension","volume":"41","author":"Kurakula KB","year":"2020","unstructured":"Kurakula KB, , Sun XQ, , Van der Feen DE, et al. Selective inhibition of histone deacetylases reverses vascular remodelling and improves right ventricle function in pulmonary hypertension. Eur Heart J, 2020; 41(Supplement 2); doi: 10.1093\/ehjci\/ehaa946.3807","journal-title":"Eur Heart J"},{"key":"e_1_3_6_384_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013339"},{"key":"e_1_3_6_385_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04874-4"},{"key":"e_1_3_6_386_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307004"},{"key":"e_1_3_6_387_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006167"},{"key":"e_1_3_6_388_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060990"},{"key":"e_1_3_6_389_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0886PP"},{"key":"e_1_3_6_390_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2014-0166TR"},{"key":"e_1_3_6_391_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-2041OC"},{"key":"e_1_3_6_392_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.07.008"},{"key":"e_1_3_6_393_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.05.261"},{"key":"e_1_3_6_394_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028034"},{"key":"e_1_3_6_395_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.09.002"},{"key":"e_1_3_6_396_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2169"},{"key":"e_1_3_6_397_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67217-w"},{"key":"e_1_3_6_398_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2016.12.015"},{"key":"e_1_3_6_399_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27987"},{"key":"e_1_3_6_400_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201107-1293OC"},{"key":"e_1_3_6_401_2","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13157"},{"key":"e_1_3_6_402_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1217LE"},{"key":"e_1_3_6_403_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010"},{"key":"e_1_3_6_404_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00337.2013"},{"key":"e_1_3_6_405_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.068"},{"key":"e_1_3_6_406_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201007-1027OC"},{"key":"e_1_3_6_407_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00132.2016"},{"key":"e_1_3_6_408_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.09.034"},{"key":"e_1_3_6_409_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000033522.37861.69"},{"key":"e_1_3_6_410_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911339"},{"key":"e_1_3_6_411_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.000077"},{"key":"e_1_3_6_412_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201801-0022LE"},{"key":"e_1_3_6_413_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100245"},{"key":"e_1_3_6_414_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.01.013"},{"key":"e_1_3_6_415_2","first-page":"A6727","article-title":"Pulmonary hypertension and anastrozole (Phantom): A randomized clinical trial","author":"Kawut SM","year":"2023","unstructured":"Kawut SM, , Feng R, , Zamanian RT, et al. Pulmonary hypertension and anastrozole (Phantom): A randomized clinical trial. Am J Respir Crit Care Med, 2023; A6727\u2013A6727.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_6_416_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00293.2011"},{"key":"e_1_3_6_417_2","first-page":"A1938","article-title":"Thioridazine improves pulmonary arterial pressure in the Su5416\/chronic hypoxia rat model of severe pulmonary arterial hypertension","volume":"191","author":"Foster WS","year":"2015","unstructured":"Foster WS, , Deng Y, , Taha M, et al. Thioridazine improves pulmonary arterial pressure in the Su5416\/chronic hypoxia rat model of severe pulmonary arterial hypertension. Am J Resp Crit Care Med, 2015; 191:A1938.","journal-title":"Am J Resp Crit Care Med"},{"issue":"1","key":"e_1_3_6_418_2","first-page":"CD003545","article-title":"Trifluoperazine for schizophrenia","volume":"2004","author":"Marques LO","year":"2004","unstructured":"Marques LO, , Lima MS, , Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev, 2004; 2004(1):CD003545; doi: 10.1002\/14651858.CD003545.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_6_419_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062919"},{"key":"e_1_3_6_420_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2024.0016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:44Z","timestamp":1777644704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2024.0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":419,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10,1]]}},"alternative-id":["10.1089\/jamp.2024.0016"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2024.0016","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}